Latest Insider Transactions at Flexion Therapeutics Inc (FLXN)
This section provides a real-time view of insider transactions for Flexion Therapeutics Inc (FLXN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Flexion Therapeutics Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Flexion Therapeutics Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 19
2021
|
Newtyn Management, LLC > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
5,900,000
-100.0%
|
-
|
|
Nov 19
2021
|
Michael D. Clayman President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
787,052
-100.0%
|
$6,296,416
$8.5 P/Share
|
|
Nov 19
2021
|
Michael D. Clayman President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
335,498
-100.0%
|
$2,683,984
$8.5 P/Share
|
|
Nov 19
2021
|
William T. Andrews Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
34,250
-100.0%
|
$274,000
$8.5 P/Share
|
|
Nov 19
2021
|
Frederick W Driscoll Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
30,680
-100.0%
|
$245,440
$8.5 P/Share
|
|
Nov 19
2021
|
Christina Willwerth Chief Strategy Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
141,241
-100.0%
|
$1,129,928
$8.5 P/Share
|
|
Nov 19
2021
|
Melissa Layman Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
103,956
-100.0%
|
$831,648
$8.5 P/Share
|
|
Nov 19
2021
|
Kerry Wentworth Chief Regulatory Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
6,000
-100.0%
|
$48,000
$8.5 P/Share
|
|
Nov 19
2021
|
Kerry Wentworth Chief Regulatory Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
140,843
-100.0%
|
$1,126,744
$8.5 P/Share
|
|
Nov 19
2021
|
Adam Muzikant Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
103,666
-100.0%
|
$829,328
$8.5 P/Share
|
|
Nov 19
2021
|
Mark S. Levine General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
133,486
-100.0%
|
$1,067,888
$8.5 P/Share
|
|
Nov 19
2021
|
Patrick J Mahaffy Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
39,824
-100.0%
|
$318,592
$8.5 P/Share
|
|
Nov 19
2021
|
Scott A Canute Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,000
-100.0%
|
$72,000
$8.5 P/Share
|
|
Nov 19
2021
|
Samuel D Colella Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,487,564
-100.0%
|
$11,900,512
$8.5 P/Share
|
|
Nov 19
2021
|
Samuel D Colella Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,000
-100.0%
|
$72,000
$8.5 P/Share
|
|
Nov 19
2021
|
Elizabeth Kwo Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,500
-100.0%
|
$36,000
$8.5 P/Share
|
|
Nov 19
2021
|
Heath Lukatch Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,000
-100.0%
|
$72,000
$8.5 P/Share
|
|
Nov 19
2021
|
C Ann Merrifield Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
19,000
-100.0%
|
$152,000
$8.5 P/Share
|
|
Nov 19
2021
|
Alan Milinazzo Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,450
-100.0%
|
$219,600
$8.5 P/Share
|
|
Nov 19
2021
|
Mark Stejbach Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,631
-100.0%
|
$101,048
$8.5 P/Share
|
|
Aug 02
2021
|
William T. Andrews Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,250
+50.0%
|
-
|
|
Jul 19
2021
|
Michael D. Clayman President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,859
-3.97%
|
-
|
|
Jul 19
2021
|
Mark S. Levine General Counsel |
SELL
Open market or private sale
|
Direct |
3,945
-2.87%
|
$23,670
$6.45 P/Share
|
|
Jul 19
2021
|
Adam Muzikant Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,870
-1.77%
|
$11,220
$6.45 P/Share
|
|
Jul 19
2021
|
Kerry Wentworth Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
3,944
-2.73%
|
$23,664
$6.45 P/Share
|
|
Jul 19
2021
|
Christina Willwerth Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
3,945
-2.72%
|
$23,670
$6.45 P/Share
|
|
Jun 24
2021
|
Alan Milinazzo Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+14.08%
|
-
|
|
Jun 24
2021
|
Patrick J Mahaffy Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+10.15%
|
-
|
|
Jun 24
2021
|
Heath Lukatch Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+33.33%
|
-
|
|
Jun 24
2021
|
Mark Stejbach Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+26.27%
|
-
|
|
Jun 24
2021
|
Samuel D Colella Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+28.67%
|
-
|
|
Jun 24
2021
|
Scott A Canute Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+33.33%
|
-
|
|
Jun 24
2021
|
C Ann Merrifield Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+19.15%
|
-
|
|
Jun 24
2021
|
Elizabeth Kwo Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+50.0%
|
-
|
|
Jun 21
2021
|
Michael D. Clayman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,700
+0.49%
|
$11,900
$7.78 P/Share
|
|
Jun 21
2021
|
Kerry Wentworth Chief Regulatory Officer |
BUY
Grant, award, or other acquisition
|
Direct |
539
+0.37%
|
$3,773
$7.78 P/Share
|
|
Jun 21
2021
|
Adam Muzikant Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,081
+1.93%
|
$14,567
$7.78 P/Share
|
|
Jun 01
2021
|
Frederick W Driscoll Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,000
+47.72%
|
-
|
|
May 10
2021
|
David Arkowitz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,229
-1.0%
|
$15,603
$7.23 P/Share
|
|
Mar 15
2021
|
Melissa Layman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,520
-4.17%
|
$49,720
$11.8 P/Share
|
|
Mar 01
2021
|
Michael D. Clayman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
106,100
+22.15%
|
-
|
|
Mar 01
2021
|
Melissa Layman Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,100
+15.63%
|
-
|
|
Mar 01
2021
|
David Arkowitz Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,900
+15.02%
|
-
|
|
Mar 01
2021
|
Scott Kelley Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+17.29%
|
-
|
|
Mar 01
2021
|
Mark S. Levine General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+17.92%
|
-
|
|
Mar 01
2021
|
Christina Willwerth Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+17.12%
|
-
|
|
Mar 01
2021
|
Kerry Wentworth Chief Regulatory Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+17.26%
|
-
|
|
Mar 01
2021
|
Adam Muzikant Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+22.48%
|
-
|
|
Feb 01
2021
|
Michael D. Clayman President and CEO |
SELL
Bona fide gift
|
Direct |
21,099
-5.73%
|
-
|
|
Jan 28
2021
|
Michael D. Clayman President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,776
-3.18%
|
$105,312
$12.37 P/Share
|